Using engineered extracellular vesicles and growth factors to improve bone healing
Dual Delivery of Engineered EVs and Growth Factor for Bone Regeneration
This study is looking at a new way to help heal bone injuries in people with type 2 diabetes by using special tiny particles and a growth factor to boost bone repair and reduce inflammation, making recovery easier and more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11076831 on NIH RePORTER |
What this research studies
This research investigates how engineered extracellular vesicles (EVs) combined with a growth factor can enhance bone regeneration, particularly in patients with type 2 diabetes. The study focuses on the role of the immune system in bone healing and aims to address the challenges posed by inflammation in these patients. By utilizing a dual delivery system that combines MSC-derived EVs with a well-known bone growth factor, the research seeks to improve treatment outcomes for bone injuries. Patients may benefit from a novel approach that targets both bone repair and inflammation simultaneously.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with type 2 diabetes who are experiencing challenges with bone healing.
Not a fit: Patients without type 2 diabetes or those not facing issues related to bone healing may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for bone healing in patients with type 2 diabetes.
How similar studies have performed: Other research has shown promise in using engineered EVs for tissue repair, suggesting that this approach could be effective.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Kang, Miya — University of Illinois at Chicago
- Study coordinator: Kang, Miya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.